Medtronic plc (ETR:2M6)
Germany
· Delayed Price · Currency is EUR 73.40
+0.05 (0.07%)
Jun 27, 2025, 5:35 PM CET
Revenue by Product
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
Cardiac Rhythm & Heart Failure | 6.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiac Rhythm & Heart Failure Growth | 6.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Diabetes | 2.76B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Diabetes Growth | 10.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Structural Heart & Aortic | 3.55B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Structural Heart & Aortic Growth | 5.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Coronary & Peripheral Vascular | 2.54B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Coronary & Peripheral Vascular Growth | 2.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cranial & Spinal Technologies | 4.97B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cranial & Spinal Technologies Growth | 4.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty Therapies | 2.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty Therapies Growth | 1.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuromodulation | 1.93B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuromodulation Growth | 10.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Surgical & Endoscopy | 6.50B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Surgical & Endoscopy Growth | -0.15% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Acute Care & Monitoring | 1.91B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Acute Care & Monitoring Growth | 0.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Segment | 137.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Segment Growth | -37.56% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg1 | -89.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
Cardiovascular Operating Profit | 4.80B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular Operating Profit Growth | 7.31% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuroscience Operating Profit | 4.18B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuroscience Operating Profit Growth | 6.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Surgical Operating Profit | 3.04B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Surgical Operating Profit Growth | -4.43% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Diabetes Operating Profit | 491.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Diabetes Operating Profit Growth | 24.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 | -6.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 Growth | 8.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
U.S. | 17.17B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
U.S. Growth | 3.67% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Non-U.S. Developed Markets | 10.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Non-U.S. Developed Markets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Emerging Markets | 6.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Emerging Markets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
Total Organic Revenue Growth | 4.90% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular Organic Revenue Growth | 6.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuroscience Organic Revenue Growth | 5.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Surgical Organic Revenue Growth | 0.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Diabetes Organic Revenue Growth | 11.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|